Prophylactic treatment for graft-versus-host disease
The prophylactic treatment for graft-versus-host disease (GVHD) followed the current standard of care. A combination of cyclophosphamide (Cy) and anti-thymocyte globulin (ATG) was used for MSD-HSCT (matched sibling donor HSCT). Anti-CD25 monoclonal antibodies were added for UD-HSCT (unrelated donors HSCT). In the HID-HSCT (haploidentical HSCT) group, methotrexate (MTX), ,mycophenolate mofetil (MMF), and an anti-CD25 monoclonal antibody were used based on previous recommendations [5].